Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The development of hepatocellular carcinoma (HCC) is probably related to infection with hepatitis B virus (HBV). Hepatocytes in livers of patients with HCC have been reported to show putative preneoplastic changes such as hyperplasia, dysplasia, or adenomatous regeneration. To determine quantitatively whether these morphologic changes are associated with HBV-infected cells, the authors performed morphometry of hepatitis B surface antigen (HBsAg)-positive hepatocytes in the nontumorous portion of 10 livers with HCC and in 10 livers without HCC. The diameter of nuclei and cytoplasm of HBsAg-positive hepatocytes was measured after demonstration of HBsAg by the peroxidase-antiperoxidase method. As controls, HBsAg-negative hepatocytes in the same liver sections were measured as well as hepatocytes of 20 age-matched HBsAg-negative patients with normal liver or alcoholic cirrhosis. HBsAg-positive hepatocytes exhibited significantly larger nuclei and a higher nucleocytoplasmic ratio than control hepatocytes. In addition, HBsAg-positive cells were often arranged in foci that consisted of two cell populations: hypertrophic (enlarged nuclei and nucleocytoplasmic ratio) and hyperplastic (two-cell-thick plates of small cells with a high nucleocytoplasmic ratio). While precancerous cells have been difficult to identify, these morphologic changes are frequently associated with the development of malignant neoplasia.
 ...
PMID:Morphometric study of hepatocytes containing hepatitis B surface antigen. 632 Jun 48

Using the rat hepatoma calcium-binding protein, oncomodulin, from Morris hepatoma 5123tc, an antiserum has been raised in rabbits useful for immunostaining of this tumor protein. The peroxidase-antiperoxidase (PAP) technique has been used to demonstrate oncomodulin in sections of Morris rat hepatomas 5123D, 5123tc, 7288Ctc, and 7777 fixed with Bouin's or Carnoy's fixatives, or using freeze substitution. Oncomodulin-specific staining was also shown by a hepatoma metastasis in lung. Optimal conditions for the indirect fluorescent antibody technique were established to demonstrate oncomodulin in virally transformed NRK cells (ASV-NRK). In both tumors and cultured neoplastic cells staining appeared which suggested that oncomodulin might occur in nucleus and cytoplasm. Normal untransformed tissues and uninfected cells did not show oncomodulin staining.
 ...
PMID:Immunocytochemical detection of oncomodulin in tumor tissue. 638 59

The subcellular and intralobular distributions of a protein which specifically inhibits the proliferation of normal liver cells were determined in rat liver, using a combination of immunological and biochemical techniques. The IgG fraction from an antiserum raised against the hepatic proliferation inhibitor was isolated by protein A-Sepharose CL-4B chromatography and shown to be highly specific for the antigen using electroimmunodiffusion and affinity chromatography. To determine the intracellular location of the inhibitor, subcellular fractions were prepared from adult rat livers by differential centrifugation. The cytoplasmic fraction contained the biologically active cytostatic inhibitor, whereas the nuclear and mitochondrial fractions were inactive. Cytoplasmic localization of the hepatic proliferation inhibitor was further confirmed by anion exchange high performance liquid chromatography and by double immunodiffusion with the anti-hepatic proliferation inhibitor IgG. When liver sections were subjected to histochemical staining mediated through the immune IgG and an avidin-biotinylated horseradish peroxidase complex, the parenchymal liver cells were stained, but endothelial and connective tissue cells were not. Although some staining was evident throughout the liver parenchyma, the most intensely stained cells were located in the centrilobular region. Moreover, an age-dependent increase in the staining intensity and/or in the number of cells containing the proliferation inhibitor was observed. Preliminary experiments showed that little, if any, staining occurred in hepatocellular carcinoma cells. This highly specific IgG can be used to monitor alterations in the content and location of hepatic proliferation inhibitor in proliferative disorders of the liver.
 ...
PMID:Distribution and subcellular localization of a hepatic proliferation inhibitor in rat liver. 642 Apr 14

Three Novikoff hepatoma protein antigens (approximately Mr = 39,000, 49,000, and 56,000) were partially purified from Novikoff hepatoma chromatin. Rabbit antiserum to these three proteins was used to examine various rat tissues for the presence of these antigens. Immunological specificity of the antiserum was assessed using quantitative microcomplement fixation assay or by visualization of the immunoreactive complexes with peroxidase-antiperoxidase procedure after transferring the electrophoretically separated proteins to nitrocellulose sheets. The immunoreactivity was localized with the three proteins p39, p49, and p56 in Novikoff hepatoma. The p56 protein was found to be present in normal rat liver, 24-h regenerating rat liver, fetal rat liver, or kidney, albeit in much smaller amounts as found in Novikoff hepatoma. the p49 and p39 antigens were specific for Novikoff hepatoma. Immunoabsorption experiments confirmed the specificity of this antiserum. Assessment of various subcellular fractions of Novikoff hepatoma revealed that the p39, p49, and p56 protein antigens are present in the cytoplasmic fractions as well as in isolated chromatin.
 ...
PMID:Tissue specificity and cellular distribution of Novikoff hepatoma antigenic proteins p39, p49, and p56. 726 43

To determine if hyperplastic and neoplastic lesions from medaka showed similar immunoreactivity to intermediate filament antibodies as the tissues of origin, two week old medaka were exposed to 10 or 20 mg/L of methylazoxymethanol acetate for two hours and transferred to clean water for up to six months. Using a streptavidin peroxidase method, paraffin embedded Bouins fixed neoplasms were incubated with cytokeratin, vimentin, or neurofilament antibodies. Like their nonneoplastic cellular counterparts, hepatocellular carcinoma, pancreatic acinar carcinoma and mesenchymal neoplasms including hemangioma and hemangiopericytoma reacted negatively to cytokeratin antibodies. Cholangiocarcinoma, mesothelioma, and proliferative lesions containing biliary epithelial cells reacted positively to cytokeratin antibodies. All neoplasms and proliferative lesions were negative with vimentin and neurofilament antibodies. These data indicate that while some epithelial neoplasms showed cytokeratin reactivity similar to the parent tissues, additional markers are needed to identify mesenchymal tissues and neoplasms.
 ...
PMID:Intermediate filament reactivity in hyperplastic and neoplastic lesions from medaka (Oryzias latipes). 753 29

Immunohistochemical methods have been used to localize an HCV antigen on paraffin embedded liver tissue sections by means of monoclonal antibodies to C100-3 nonstructural protein. Peroxidase-antiperoxidase, alkaline phosphatase-antialkaline phosphatase, biotin-streptavidin-peroxidase and immunogold silver staining methods showed a nuclear staining of the hepatocytes in cases of chronic hepatitis with positive HCV serology, alcoholic liver disease and hepatocarcinoma. No cross reactions were observed with viral hepatitis B and delta antigens. The strongest reaction without background staining was obtained with immunogold silver staining. Nuclear localization was compared to the cytoplasmic staining described in the literature.
 ...
PMID:Nuclear immunostaining of hepatitis C infected hepatocytes with monoclonal antibodies to C100-3 nonstructural protein. Comparison of immunogold silver staining with other immunohistochemical methods. 787 66

The aim of this study was to evaluate the immunohistochemical expression of epidermal growth factor (EGFR) and c-erb-B-2 oncoprotein in a series of 71 hepatocellular carcinomas as well as in the adjacent hepatic tissue and to assess any correlation with HBsAg expression. The total of the 71 hepatocellular carcinomas (HCCs) was classified into 17 low grade and 54 high grade cases with adjacent non-neoplastic liver parenchyma, observed in 14 and 28 cases respectively. Coexisting cirrhosis or fibrosis was noticed in the adjacent non-neoplastic parenchyma in 12 cases of low grade and 22 cases of high grade HCC. The immunohistochemical avidin-biotin-peroxidase complex (ABC) method was performed on formalin-fixed paraffin sections for the detection of EGFR, c-erb-B-2 oncoprotein and HBsAg using monoclonal antibodies. The expression of c-erb-B-2 was observed in 29.5% (21/71) of the HCCs showing no statistically significant correlation with histological grade. The c-erb-B-2 was also detected in the adjacent non-neoplastic parenchyma in 7/14 low grade HCCs, and in 9/28 high grade HCCs. No statistically significant differences in c-erb-B-2 oncoprotein expression were observed between the HCCs and the adjacent non-neoplastic parenchyma. In addition, HBsAg was detected in 10/42 examined cases of HCC with adjacent non-neoplastic parenchyma, while only 4 cases of HCCs were simultaneously positive for c-erb-B-2 and HBsAg. EGFR was detected in only 3/71 cases of HCC, while the antigen was not detected at all in the adjacent non neoplastic parenchyma. HBsAg expression was not observed in any of the EGFR-positive HCCs. Our results suggest that both c-erb-B-2-oncoprotein and EGFR do not seem to be predominantly involved in the transformation of hepatocytes to the malignant phenotype.
 ...
PMID:C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. 789 39

The expression of transforming growth factor-alpha (TGF-alpha) was studied in 33 surgically excised human hepatocellular carcinomas (HCCs), focal nodular hyperplasias (FNHs), and the surrounding liver tissue from patients who were life-long residents of Hungary. Monoclonal antibodies were used to localize TGF-alpha and hepatitis B surface antigen (HBsAg) using an avidin-biotin-peroxidase immunohistochemical method on paraffin-embedded sections. Transforming growth factor-alpha was detected in the tumor tissue in 13 of 16 patients with HCC (81%) and in 12 of 17 patients with FNH (71%). Three patients with HCC were actively infected with hepatitis B virus, indicated by the detection of HBsAg in the serum and in adjacent nontumorous liver. Transforming growth factor-alpha was detected in the same nontumorous hepatocytes as HBsAg, often in areas of the hepatocyte cytoplasm, with a "ground glass" appearance. Bile duct cells were stained for TGF-alpha in the surrounding nontumorous liver tissue and a more intensive immunostaining was observed in the proliferating bile ducts in the FNH cases, which suggests that TGF-alpha may participate in the growth regulation of bile ducts.
 ...
PMID:Overexpression of transforming growth factor-alpha in hepatocellular carcinoma and focal nodular hyperplasia from European patients. 802 23

A convenient and sensitive indirect sandwich ELISA test was developed for measuring both 63 kDa human alpha 2-HS secreted by human hepatoma cell lines and the 59 kDa alpha 2-HS species present in serum/plasma. Monoclonal and rabbit antibodies to plasma alpha 2-HS were produced and selected by immunoprecipitation techniques using iodinated alpha 2-HS or 35S-labeled alpha 2-HS. Various monoclonal antibodies recognizing both forms of the protein were coated onto microtiter plates and after binding of alpha 2-HS, biotinylated monoclonal antibodies with compatible binding or biotinylated immunopurified F(ab')2 fragments from the rabbit antiserum were added and subsequently revealed with avidin-biotin peroxidase complex. Formats using a rabbit detector antibody were the most sensitive and one was selected for the whole study. The test developed was capable of detecting plasma alpha 2-HS devoid of connecting peptide and HepG2 hepatoma cell line derived alpha 2-HS at the ng/ml level. The test has been used to measure levels of alpha 2-HS in both serum and supernatants from HepG2 cell lines.
 ...
PMID:Production and characterization of monoclonal and polyclonal antibodies to human alpha 2-HS: development of a two-site ELISA test. 803 71

A one-step sandwich enzyme immunoassay (EIA) for human matrix metalloproteinase 2 (MMP-2, 72-kDa gelatinase/type IV collagenase, EC 3.4.24.24) was established with a pair of monoclonal antibodies prepared against the precursor form of MMP-2 (proMMP-2) purified from the conditioned medium of human skin fibroblasts or against a synthetic peptide corresponding to the N-terminal domain of proMMP-2. ProMMP-2 in samples was allowed to simultaneously react with both solid-phase and peroxidase-labeled antibodies. Sensitivity of this EIA system was 2.4 pg/assay (0.24 microgram/l) and linearity was obtained between 10 and 5,000 pg/assay (1.0-500 micrograms/l). The EIA system recognized both the free form of proMMP-2 and its complex form with TIMP-2 with the same degree of immunoreactivity. ProMMP-2 levels in human sera from patients in various disease states were analyzed. In sera from patients with hyperthyroidism (12), primary biliary cirrhosis (8) and hepatocellular carcinoma (11), 749 +/- 166, 716 +/- 135 and 686 +/- 236 micrograms/l of proMMP-2 were detected, respectively and these were significantly higher than that observed in 213 normal human sera (570 +/- 118 micrograms/l). In contrast, the levels in sera from 33 patients with osteoarthritis (449 +/- 72 micrograms/l), 45 with rheumatoid arthritis (408 +/- 139 micrograms/l), 13 with stomach cancer (427 +/- 103 micrograms/l) and 10 with pancreatic cancer (422 +/- 130 micrograms/l) were significantly lower than that found in normal sera. Immunoblot and gel filtration analyses showed that human sera contain several MMP-2 species in addition to proMMP-2 which exist in a complex form with TIMP-2.
 ...
PMID:A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. 814 45


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>